BBIO

33.02

4.48% -1.55

Pre-mercato: 33.08 0.06 +0.18%

Bridgebio Pharma Inc (BBIO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BBIO Giù? Forum Previsione

Precedente Chiudi:

$34.57

Aprire:

$33.85

Volume 24 ore:

2.81M

Relative Volume:

1.02

Capitalizzazione di mercato:

$6.28B

Reddito:

$217.77M

Utile/perdita netta:

$-438.86M

Rapporto P/E:

-13.70

EPS:

-2.41

Flusso di cassa netto:

$-456.33M

1 W Prestazione:

-10.13%

1M Prestazione:

-5.39%

6M Prestazione:

+33.15%

1 anno Prestazione:

+10.14%

Intervallo 1D:

$32.84

$34.50

Intervallo di 1 settimana:

$32.84

$37.06

Portata 52W:

$21.62

$39.47

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Nome

Bridgebio Pharma Inc

Settore

Healthcare (1165)

Industria

Biotechnology (681)

Telefono

(650) 391-9740

Indirizzo

3160 PORTER DR., PALO ALTO, CA

Dipendente

730

Cinguettio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

BBIO's Discussions on Twitter

Confronta BBIO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BBIO Bridgebio Pharma Inc	33.02	6.28B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	484.74	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	617.00	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	567.09	34.59B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	255.76	33.10B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	271.04	29.15B	3.81B	-644.79M	-669.77M	-6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-10-03	Iniziato	Oppenheimer	Perform
2024-09-04	Iniziato	Piper Sandler	Overweight
2024-03-21	Ripresa	Raymond James	Outperform
2024-01-31	Iniziato	BMO Capital Markets	Market Perform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-11-07	Iniziato	Citigroup	Buy
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-07-18	Downgrade	Jefferies	Buy → Hold
2023-04-19	Iniziato	Evercore ISI	Outperform
2023-02-06	Iniziato	Cowen	Outperform
2021-12-27	Reiterato	Mizuho	Buy
2021-12-27	Reiterato	SVB Leerink	Outperform
2021-09-10	Aggiornamento	BofA Securities	Neutral → Buy
2021-05-21	Iniziato	UBS	Buy
2021-03-22	Reiterato	Goldman	Buy
2021-02-22	Ripresa	JP Morgan	Overweight
2021-02-09	Ripresa	Goldman	Buy
2021-01-11	Reiterato	H.C. Wainwright	Buy
2020-12-10	Reiterato	H.C. Wainwright	Buy
2020-06-25	Iniziato	BofA/Merrill	Neutral
2020-05-19	Iniziato	BTIG Research	Buy
2020-04-13	Iniziato	H.C. Wainwright	Buy
2020-02-19	Iniziato	Mizuho	Buy
2019-07-26	Iniziato	Raymond James	Outperform
2019-07-22	Iniziato	BMO Capital Markets	Outperform
2019-07-22	Iniziato	Goldman	Buy
2019-07-22	Iniziato	JP Morgan	Overweight
2019-07-22	Iniziato	Jefferies	Buy
2019-07-22	Iniziato	Piper Jaffray	Overweight
2019-07-22	Iniziato	SVB Leerink	Outperform

Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

Apr 01, 2025

Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada

Apr 01, 2025

Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan

Apr 01, 2025

Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa

Mar 31, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq

Mar 31, 2025

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener

Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com

Mar 31, 2025

Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan

Mar 31, 2025

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - Marketscreener.com

Mar 31, 2025

Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India

Mar 31, 2025

Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Mar 31, 2025

Mar 29, 2025

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025

(BBIO) Technical Data - news.stocktradersdaily.com

Mar 29, 2025

Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN

Mar 29, 2025

Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada

Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India

Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa

Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025

BridgeBio’s Beyonttra approved in Japan - The Pharma Letter

Mar 27, 2025

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com

Mar 27, 2025

BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq

Mar 27, 2025

Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - Marketscreener.com

Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra - Investing.com

Mar 27, 2025

Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan

Mar 27, 2025

Mar 24, 2025

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times

Mar 24, 2025

BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq

Mar 24, 2025

Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR

Mar 24, 2025

Mar 23, 2025

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN

Mar 23, 2025

Mar 22, 2025